UPDATE: GW’s Epidiolex on April 19 received a unanimous recommendation from the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Association. The following article has been updated to reflect that decision. This is a make-or-break spring for GW Pharmaceuticals and its billion-dollar investment in a cannabidiol-based drug. The London-based firm aims to develop the first FDA-approved medicine from plant-derived cannabis compounds. The U.S.